The combination of ACE inhibition plus sympathetic denervation is superior to ACE inhibitor monotherapy in the rat renal ablation model

Nephron - Experimental Nephrology

Volumn 105, Issue 4, 2007, Pages

  Hamar, Peter ^a,c   Kokeny, Gabor ^a,c   Liptak, Peter ^b,c   Krtil, Jan ^c   Adamczak, Marcin ^c   Amann, Kerstin ^d   Ritz, Eberhard ^c   Gross, Marie Luise ^c  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

ACE inhibitor, progression; Remnant kidney model; Renin angiotensin system; Sympathetic system

Indexed keywords

3 NITROTYROSINE; COLLAGEN TYPE 4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRINKING WATER; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NEURONAL NITRIC OXIDE SYNTHASE; QUINAPRIL; TAP WATER; TRANSFORMING GROWTH FACTOR BETA1;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; AUTONOMIC DENERVATION; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; DORSAL RHIZOTOMY; DORSAL ROOT; EXPERIMENTAL MODEL; GLOMERULOSCLEROSIS; HYPERTROPHY; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; KIDNEY; MALE; MORPHOMETRICS; NONHUMAN; OXIDATIVE STRESS; PARTIAL NEPHRECTOMY; PODOCYTE; PRIORITY JOURNAL; RAT; RENAL PROTECTION; SYMPATHETIC INNERVATION; TELEMETRY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; KIDNEY FAILURE, CHRONIC; MALE; NEPHRECTOMY; RATS; RATS, SPRAGUE-DAWLEY; SYMPATHECTOMY; TREATMENT OUTCOME;

EID: 33947690764     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100494     Document Type: Article

References (35)

1. Rennke HG, Klein PS: Pathogenesis and significance of nonprimary focal and segmental glomerulosclerosis. Am J Kidney Dis 1989;13:443-456.
2. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 1998;339:1448-1456.
3. Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
4. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-1462.
5. Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
6. Campese VM, Kogosov E: Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995;25:878-882.
7. Ye S, Zhong H, Yanamadala V, Campese VM: Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 2002;15:717-724.
8. Amann K, Rump LC, Simonaviciene A, et al: Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 2000;11:1469-1478.
9. Amann K, Koch A, Hofstetter J, et al: Glomerulosclerosis and progression: effect of subantihypertensive doses of alpha and beta blockers. Kidney Int 2001;60:1309-1323.
10. Rump LC, Oberhauser V: Chronic renal failure - taming the sympathetic nervous system! New approach to delaying progression. MMW Fortschr Med 1999;141:39-41.
11. Hostetter TH: The next treatments of chronic kidney disease: if we find them, can we test them? J Am Soc Nephrol 2002;13:3024-3026.
12. Benigni A, Zoja C, Corna D, et al: Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 2003;14:1816-1824.
13. 3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 1998;53:1696-1705.
14. Bunag RD: Validation in awake rats of a tailcuff method for measuring systolic pressure. J Appl Physiol 1973;34:279-282.
15. Magnotti RA Jr, Stephens GW, Rogers RK, Pesce AJ: Microplate measurement of urinary albumin and creatinine. Clin Chem 1989;35:1371-1375.
16. el Nahas AM, Zoob SN, Evans DJ, Rees AJ: Chronic renal failure after nephrotoxic nephritis in rats:contributions to progression. Kidney Int 1987;32:173-180.
17. Kang DH, Hughes J, Mazzali M, et al: Impaired angiogenesis in the remnant kidney model. II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 2001;12:1448-1457.
18. Amann K, Nichols C, Tornig J, et al: Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant 1996;11:1003-1011.
19. Torry RJ, Connell PM, O'Brien DM, et al: Sympathectomy stimulates capillary but not precapillary growth in hypertrophic hearts. Am J Physiol 1991;260:H1515-H1521.
20. Skov K, Nyengaard JR, Patwardan A, Mulvany MJ: Large juxtamedullary glomeruli and afferent arterioles in healthy primates. Kidney Int 1999;55:1462-1469.
21. Culy CR, Jarvis B: Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders. Drugs 2002;62:339-385.
22. Orth SR, Amann K, Strojek K, Ritz E: Sympathetic overactivity and arterial hypertension in renal failure. Nephrol Dial Transplant 2001;16(suppl 1):67-69.
23. Lohmeier TE: The sympathetic nervous system and long-term blood pressure regulation. Am J Hypertens 2001;14:147S-154S.
24. LeNoble LM, Lappe RW, Brody MJ, et al: Selective efferent chemical sympathectomy of rat kidneys. Am J Physiol 1985;249:R496-R501.
25. Szenasi G, Bencsath P, Szalay L, Takacs L: Fasting induces denervation natriuresis in the conscious rat. Am J Physiol 1985;249:F753-F758.
26. Neumann J, Ligtenberg G, Oey L, et al: Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol 2004;15:2902-2907.
27. Vonend O, Marsalek P, Russ H, et al: Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 2003;21:1709-1717.
28. Strojek K, Grzeszczak W, Gorska J, et al: Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol 2001;12:602-605.
29. Rosenberg ME, Hostetter TH: Comparative effects of antihypertensives on proteinuria: angiotensin-converting enzyme inhibitor versus alpha 1-antagonist. Am J Kidney Dis 1991;18:472-482.
30. DiBona GF: Neural control of the kidney: past, present, and future. Hypertension 2003;41:621-624.
31. DiBona GF: The sympathetic nervous system and hypertension: recent developments. Hypertension 2004;43:147-150.
32. Boivin V, Jahns R, Gambaryan S, et al: Immunofluorescent imaging of beta 1- and beta 2-adrenergic receptors in rat kidney. Kidney Int 2001;59:515-531.
33. Durvasula RV, Petermann AT, Hiromura K, et al: Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 2004;65:30-39.
34. Wolf G, Mueller E, Stahl RA, Ziyadeh FN: Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest 1993;92:1366-1372.
35. Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431-2437.